Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07122492 · ClinicalTrials.gov registry record · NA
A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)
A NA study, sponsored by Eastern Cooperative Oncology Group.
- Not yet
- Registry status
- NA
- Development phase
- 800
- Enrollment target
NCT07122492: Clinical Trial NA study, sponsored by Eastern Cooperative Oncology Group.
NCT07122492 is a NA study that has not yet begun recruiting, run by Eastern Cooperative Oncology Group. The registered enrollment target is 800 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07122492, a NA study, has not yet begun recruiting, sponsored by Eastern Cooperative Oncology Group.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
Study Summary
The goal of this study is to determine if the intervention or if general information about being a breast cancer survivor can help Breast Cancer Survivors reduce their fear of recurrence. The main question it aims to answer are: Can the FoRtitude intervention lower the fear of recurrence for Breast Cancer Survivors? Participants will: Answer questions about their fear of recurrence. Be randomized to 1 of the 3 following options: (1) a weblink to access an eHealth intervention which includes a website and an optional interactive text-messaging feature, (2) a weblink to a non-interactive website that will include links to external websites with general information that may be helpful for Breast Cancer Survivors, or (3) you will need to talk with your oncology team about your concerns about recurrence or seek psychosocial care in the community. Be asked to fill out questionnaires 5 times for up to 18 months.
Primary Outcome
Fear of Cancer Recurrence Inventory (FCRI) modified total score 143 (without coping or reassurance subscale items) measured during the study period. A graphical exploration of the data will be performed by examining the distribution of FCRI score at each follow up timepoint, as well as the changes in FCRI between the baseline and follow up visits. 1-month post-intervention completion (3 months post-randomization) will be defined as the primary comparison. For the primary analysis we will compare
Interventions
- BEHAVIORAL Attention Control
- BEHAVIORAL FoRtitude 2.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2029-09-01 |
| Phase | NA |
What is known before NCT07122492 opens enrollment
NCT07122492 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Attention Control is the first listed.
NCT07122492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07122492 about?
NCT07122492 is a clinical study titled "A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)". The goal of this study is to determine if the intervention or if general information about being a breast cancer survivor can help Breast Cancer Survivors reduce their fear of recurrence. The main question it aims to answer are: Can the FoRtitude intervention lower the fear of recurrence for Breast...
What is the current status of trial NCT07122492?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2025-09-01. Estimated completion is 2029-09-01.
What interventions are being tested in trial NCT07122492?
The interventions under investigation include: Attention Control (BEHAVIORAL), FoRtitude 2.0 (BEHAVIORAL).
Who is sponsoring clinical trial NCT07122492?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07122492's enrollment target sits among peer trials
800 135th of 2000 higher than 1,861 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI